CFTR and cystic fibrosis: When combined with ivacaftor, tezacaftor, an alternative CFTR corrector, also showed an improvement in CF patients (both F508del homozygotes and F508del heterozygotes), albeit displaying fewer respiratory-related adverse events [184].